Vanguards of Health Care by Bloomberg Intelligence
BioNTech's Richardson on Drug Pipeline
03 Oct 2024
BioNTech has a broad and diversified cancer drug pipeline extending well beyond mRNA based approaches. Sam Fazeli, Senior Health Care Analyst, speaks to Ryan Richardson, Chief Strategy Officer, who explains the company’s approach to drug development, hopes for drug launches and what sets it apart from rivals.See omnystudio.com/listener for privacy information.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other episodes from Vanguards of Health Care by Bloomberg Intelligence
Transcribed and ready to explore now
Aegis Ventures’ Blueprint for Building AI-Native Companies
04 Dec 2025
Vanguards of Health Care by Bloomberg Intelligence
Beta Bionics Does the Work to Reduce Insulin Pump Burden
20 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
Fosun Pharma’s Drive Beyond China
17 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
ARS Pharma’s Clinical Differentiation
13 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
Biolinq Introduces New Silicon Tech Opens Next Chapter of Glucose and Analyte Detection
06 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates
27 Oct 2025
Vanguards of Health Care by Bloomberg Intelligence